Perelman School of Medicine at the University of Pennsylvania and Abramson Cancer Center
Last Modified: January 13, 2014
Dates: April 3, 2014
Location: Smilow Center for Translational Research
Sponsoring Group: Perelman School of Medicine at the University of Pennsylvania and Abramson Cancer Center
Web Page URL: www.penncancer.org/CME/PD
Topics Covered: Personalized Dx and Rx; Leukemia; Technology and Competing Platforms; Clinical Trials; Lung and Other Solid Tumors; Melanoma
Objectives: Describe advances in genome sequencing for cancer; Explain the advantages of cancer gene panels; Review clinical applications of cancer gene panel sequencing for lung, melanoma, and leukemia
Who Should Attend: This course is designed for medical, surgical, and radiation oncologists; hematologists; pathologists; hematology/oncology fellows; oncology nurses; and other healthcare professionals involved in the treatment of patients with leukemia, melanoma, and lung cancer.
Registration Information: For more information, or to register, please contact Mary Graham at firstname.lastname@example.org
Fees: $125 Practicing Physicians; $75 Non-Penn Resident, Fellow, Nurse, and other Healthcare Professionals; $50 Faculty, Staff, Resident, Fellow and/or Student of the University of Pennsylvania
Continuing Education: Yes
Apr 16, 2012 - Bimodal genes, or molecular on/off switches, can distinguish clinically relevant subtypes of ovarian cancer and provide ideal targets for diagnostic and prognostic testing, according to a study published online April 11 in the Journal of Molecular Diagnostics.
Apr 16, 2012
Jan 30, 2014
May 23, 2011